Plus   Neg

Stock Alert: AnPac Bio-Medical Science Jumps 83%

Shares of AnPac Bio-Medical Science Co., Ltd. (ANPC), a biotechnology company, are surging almost 83 percent or $3.49 in Monday's morning trade at $7.71.

Monday, AnPac Bio-Medical Science said it has made significant progress in detecting pre-cancer diseases. The company recently completed a prospective large population screening of over 110,000 individuals using its Cancer Differentiation Analysis (CDA) technology. The follow-up study involved over 13,000 individuals assessed with high cancer risk, medium cancer risk and low cancer risk using the CDA technology.

Initial results indicated that AnPac Bio's CDA technology is capable of providing meaningful information while also screening out pre-cancer diseases. Over 20 types of pre-cancer diseases were diagnosed following initial screening utilizing CDA technology and subsequent confirmation by hospital or physical testing center health check-ups.

AnPac Bio-Medical has traded in a range of $3.15 to $12.00 in the past 52 weeks.

For comments and feedback contact: editorial@rttnews.com

Business News

Get Access to Premium Stock Alerts with RTT Intelligent Investor.
Editors Pick
Best Buy Co., Inc. is offering paid time off as vaccine benefit to all its employees amid the ongoing vaccinations against coronavirus. The company also announced bonuses to its hourly employees as a gratitude for the resilience shown by them as frontline workers during the crisis. The electronics retailer said it is offering paid time off for any employee who gets a COVID-19 vaccination. Entertainment company Walt Disney Co.'s exclusive streaming service Disney+ has added more content with the addition of the Star brand which launched today on the platform across Australia, New Zealand, Canada, and Europe. Disney+ with Star also launched today in Singapore, the first market to launch with the new general entertainment brand. Off-price retailer TJX Companies, Inc. (TJX) reported Wednesday that profit for the fourth quarter plunged from last year. Both earnings per share and sales for the quarter also missed analysts' expectations. TJX's net income for the quarter plunged to $325.52 million or $0.27 per share from $984.79...
Follow RTT